JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
The acquisition of genetic testing firm Ambry will open up new markets for Tempus, which is looking beyond the oncology field.
Quanterix to Acquire Akoya Biosciences
The deal will integrate Akoya's spatial biology capabilities with Quanterix's biomarker-detection tools for ultra-sensitive detection of protein biomarkers in blood and tissue.
Combined with a new software update, the NovaSeq X 25B 100-cycle kits can generate several billion more reads per run than previously.
Clinical customers helped Illumina place 91 NovaSeq X instruments in the fourth quarter. CFO Ankur Dhingra said many planned to use them for MRD testing.
The firm reported approximately $60 million in revenues in 2024, more than double the amount it recorded in the prior year.
Truveta Genome Project Launches With $320M Investment From Regeneron, Illumina, Health Systems
The initiative aims to generate genetic data on tens of millions of volunteers, creating the largest and most diverse database of genotypic and phenotypic information available.
Illumina Launches Pilot Proteomics Study With UK Biobank, Inks Partnership With Nvidia
In collaboration with UK Biobank and pharma partners, Illumina will analyze 50,000 samples using the upcoming Protein Prep assay and NovaSeq X Plus platform.